This is off of their website "Cannabis Science's research of CS-TATI-1 will be targeted to newly diagnosed patients infected with drug resistant virus, treatment-experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies"
Sounds like they are trying to sell an HIV cure thru misleading deceitful PRs. Good thing they are not filing those quarters, after 86 million in losses, majority in 2012- could be in trouble. Gullible investors should beware- cbds work, cbis doesnt
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.